All sponsors

Mirati Therapeutics Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO86%

Delay Index: of 7 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +20.0 months). See all sponsors →

Open Mirati Therapeutics Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
KRYSTAL-12
NCT04685135
P3Active, not recruitingMetastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer4532023-12-30 (+13 mo)
MRTX849
NCT04793958
P3Active, not recruitingAdvanced Colorectal Cancer; Metastatic Colorectal Cancer4612026-01-16 (+28 mo)
MRTX849
NCT03785249
P1/2Active, not recruitingAdvanced Cancer; Metastatic Cancer7312026-06-23 (+75 mo)
Adagrasib oral dose of 400 mg twice daily tablets
NCT05609578
P2Active, not recruitingAdvanced NSCLC; Metastatic Lung Cancer902026-09-30 (+15 mo)
Adagrasib
NCT05853575
P2Active, not recruitingAdvanced Cancer; Metastatic Cancer2002026-10-30 (+20 mo)
Adagrasib
NCT07415031
P2RecruitingSolid Tumors1702028-02-16
Adagrasib
NCT04613596
P2/3RecruitingAdvanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer6262028-10-31 (+72 mo)
Adagrasib
NCT06875310
P3RecruitingCarcinoma, Non-Small-Cell Lung6302029-09-07